The metabolic syndrome - Pathogenesis, clinical features and management

Cardiovascular Journal of South Africa

Volumn 13, Issue 4, 2002, Pages 181-186

  Lombard, L ^a   Augustyn, M N ^a   Ascott Evans, B H ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PIOGLITAZONE; ROSIGLITAZONE;

CARDIOVASCULAR DISEASE; CLINICAL FEATURE; DIABETES MELLITUS; DYSLIPIDEMIA; HUMAN; HYPERINSULINEMIA; HYPERTENSION; HYPERURICEMIA; INSULIN RESISTANCE; LIFESTYLE; METABOLIC DISORDER; OBESITY; PATHOGENESIS; REVIEW; RISK FACTOR;

HUMANS; METABOLIC SYNDROME X;

EID: 0036658559     PISSN: 10159657     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. Mak K-H, Moliterno DJ, Granger CB, et al. (GUSTO-I Investigators). Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. J Am Coll Cardiol 1997; 30: 171-179.
2. Rich-Edwards JW, Manson JE, Hennekens CH, Buring JE. The primary prevention of coronary heart disease in women. N Engl J Med 1995; 332: 1758-1765.
3. Lebovitz HE. Oral therapies for diabetic hyperglycemia. Endocrinol Metab Clin North Am 2001; 30: 909-933.
4. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
5. Kaplan NM. The deadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 1989; 149: 1514-1520.
6. Matthaei S, Stumvoli M, Kellerer M, Haring H. Pathophysiology and pharmacological treatment of insulin resistance. Endocrine Rev 2000; 21: 585-618.
7. Meigs JB, Murray AM, Nathan DM, et al. Hyperinsulinemia, Hyperglycemia and impaired hemostasis - The Framingham offspring study. JAMA 2000; 283: 221-228.
8. Fonseca V, Guba SC, Fink LM. Hyperhomocysteinemia and the endocrine system: Implications for atherosclerosis and thrombosis. Endocrine Rev 1999; 20: 738-759.
9. Calles-Escandon J, Cipola M. Diabetes and endothelial dysfunction: a clinical perspective. Endocrine Rev 2001: 22: 36-52.
10. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechte; G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996; 97: 2601-2610.
11. Dunaif A, Graf M, Mandeli J, et al. Characterization of groups of hyper-androgenic women with acanthosis nigricans, impaired glucose tolerance and/or hyperinsulinemia. J Clin Endocrinol Metab 1987; 65: 499-507.
12. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocrine Rev 1997; 18: 774-800.
13. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2000; 50: 1844-1850.
14. Meigs JB, D'Agostin, Wilson PFW, et al. Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study. Diabetes 1997; 46(10): 1594-1600.
15. Shaw JE, Zimmet PZ, McCarty D, de Courten M. Type 2 diabetes worldwide according to the new classification and criteria. Diabetes Care 2000; 23: B5-10.
16. DeFronzo RA. Glucose tolerance and aging. Diabetes 1979; 28: 1099-1101.
17. Williams G, Pickup JC. Handbook of Diabetes. 2nd edn. Oxford: Blackwell Science, 1999: 48-60.
18. Kissebah AH, Freedman DS, Peiris AN. Health risks of obesity. Med Clin North Am 1989; 73: 111-138.
19. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997; 46: 3-10.
20. Moller DE. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trend Endocrinol Metab 2000; 11: 212-217.
21. Peraldi P, Spiegelman B. TNF-Alpha and insulin resistance: summary and future prospects. Mol Cell Biochem 1998; 182: 169-175.
22. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395: 763-770.
23. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312.
24. Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia, Hyperglycemia, and impaired hemostasis - The Framingham Offspring Study. JAMA 2000; 283: 221-228.
25. Colwell JA. Treatment for the procoagulant state in type 2 diabetes. Endocrinol Metab Clin North Am 2001; 30: 1011-1027.
26. Borchard U. The Role of the sympathetic nervous system in cardiovascular disease. J Clin Basic Cardiol 2001; 4: 175-177.
27. Hansson L. Therapy of hypertension and metabolic syndrome: today's standard and tomorrow's perspectives. Blood Pressure 1998; 7(Suppl 3): 20-22.
28. Bjorntorp P, Holm G, Rosmond R, Folkow B. Hypertension and the metabolic syndrome: closely related central origin? Blood Pressure 2000; 9: 71-82.
29. Almind K, Bjorbaek C, Vetsergaard H, Hansen T, Echwald SM, Pedersen O. Amino acid polymorphisms of insulin receptor substrate-1 in non-insulin-dependant diabetes mellitus. Lancet 1993; 342: 828-832.
30. Hansen T, Anderson CB, Echwald SM, et al. Identification of a common amino acid polymorphism in the p85 alpha regulatory subunit of phosphatidylinositol 3-kinase: effects on glucose disappearance constant, glucose effectiveness and the insulin sensitivity index. Diabetes 1997; 46: 494-501.
31. Chen H, Charlat O, Tartaglia LA, et al. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996; 84: 491-495.
32. Montague CT, Farooqi IS, Whitehead JP, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997; 387: 903-908.
33. Després JP, Lemieux I, Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 2001; 322: 716-720.
34. Donahue RP, Orchard TJ. Diabetes mellitus and macrovascular complications: an epidemiological perspective. Diabetes Care 1992; 15: 1141-1155.
35. Jarrett RJ, Shipley MJ. Type 2 (non-insulin-dependant) diabetes mellitus and cardiovascular disease-putative association via common antecedents; further evidence from Whitehall Study. Diabetologia 1988; 31: 737-740.
36. Herman JB, Medalie JH, Goldbourt U. Differences in cardiovascular morbidity and mortality between previously known and newly diagnosed adult diabetics. Diabetologia 1977; 13: 229-234.
37. Rogers DL. Acanthosis nigricans. Semin Dermatol 1991; 10: 160.
38. Dunaif A, Xia J, Book C, et al. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle: A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995; 96: 801-810.
39. Deprés JP, Moorjanin S, Lupien PJ, et al. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Atherosclerosis 1990; 10: 497-511.
40. Lamarche B, Tchernof A, Mauriège P, et al. Fasting insulin and apolipoprotein B levels and low density lipoprotein particle size as risk factors for ischaemic heart disease. JAMA 1998; 279: 1955-1961.
41. Pouliot MC, Deprés JP, Lemieux S, et al. Waist circumference and abdominal saggital diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and woman. Am J Cardiol 1994; 73: 460-468.
42. Lemieux S, Prud'homme D, Tremblay A, et al. Anthropometric correlates to changes in visceral adipose tissue over 7 years in women. Int Obes Relat Metab Disord 1996; 20: 618-624.
43. Mahan LK, Escort-Stump S. Krause's Food, Nutrition and Diet Therapy, 9th edn. Philadelphia: WB Saunders Company. 1996.
44. Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ 1995; 311: 158-164.
45. Han TS, van Leer EM, Seidle JC, Lean ME. Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample. BMJ 1995; 311: 401-405.
46. ADA: Clinical Practice Recommendations 2001 - Screening for Diabetes. Diabetes Care 2001; 24: S21-S24.
47. Pyorala K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979; 2: 131-141.
48. Fontbonne A, Charles MA, Thibult N, et al. Hyperinsulinemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up. Diabetologia 1991; 34: 356-361.
49. Després JP, Lamarche B, Mauriege P. et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-957.
50. Khan CR. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 1994; 43: 1066-1082.
51. Stratton IM, Adler AI, Neil HA, et al. The association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000; 321: 405-412.
52. ADA: Clinical Practice Recommendations 2001 - Tests of Glycemia in Diabetes. Diabetes Care 2001; 24: S80-S82.
53. ADA: Clinical Practice Recommendations 2001 - Standards of Medical Care for Patients with Diabetes Mellitus. Diabetes Care 2001; 24: S33-S43.
54. Hypertension in Diabetes Study Group: HDS 1: Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993; 11: 309-317.
55. Hypertension in Diabetes Study Group: HDS 2: increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens 1993; 11: 319-325.
56. McFarlane SU, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001; 86: 713-719.
57. Daly PA, Landsberg L. Hypertension in obesity and NIDDM: Role of insulin and sympathetic nervous system. Diabetes Care 1991; 14: 240-248.
58. Austin MA, Edwards KL. Small, dense low-density lipoproteins, the insulin resistance syndrome and non-insulin-dependant diabetes. Curr Opin Lipidol 1996; 7: 167-171.
59. Goldberg IJ. Diabetic Dyslipidemia: causes and consequences. J Clin Endocrinol Metab 2001; 86(3): 965-971.
60. ADA: Clinical Practice Recommendations 2001 - Management of Dyslipidemia in Adults with Diabetes. Diabetes Care 2001; 24: S58-S61.
61. Jensen JS, Borch-Johnsen K, Jensen G, Feldt-Rasmussen B. Microalbuminuria reflects a generalized transvascular albumin leakiness in clinically healthy subjects. Clin Sci 1995; 88: 629-633.
62. Pedrinelli R, Giampietro O, Carmassi F, et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994; 344: 14-18.
63. Munshi MN, Stone A, Fink L, Fonseca V. Hyperhomocysteinemia following a methionine load in patients with non-insulin dependant diabetes mellitus and macrovascular disease. Metabolism 1996; 45: 133-135.
64. Stampfer MJ, Malinow MR, Willet WC, et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 1992; 268: 877-881.
65. Di Minno G, Davi G, Margaglione M, Cirillo F, et al. Abnormally high thromboxane biosynthesis in homozygous homocysteinuria. Evidence for platelet involvement and probucol-sensitive mechanism. J Clin Invest 1993; 92: 1400-1406.
66. Imperatore G, Riccardi G, Iovine C, Rivellese AA, Vaccaro O. Plasma fibrinogen: a new factor of the metabolic syndrome: a population-based study. Diabetes Care 1998; 21: 649-654.
67. Byberg L, Siegbahn A, Berglund L, et al. Plasminogen activator inhibitor-1 activity is independently related to both insulin sensitivity and serum triglycerides in 70-year-old men. Arterioscler Thromb Vasc Biol 1998; 18: 258-264.
68. Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 diabetes. Diabetes Care 2001; 24: 1476-1485.
69. ADA: Clinical Practice Recommendations 2001 - Aspirin Therapy in Diabetes. Diabetes Care 2001; 24: S62-S63.
70. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999; 131: 7-13.
71. Leyva F, Wingove CS, Godsland IF, Stevenson JC. The glycolytic pathway to coronary heart disease: a hypothesis. Metabolism 1998; 47: 657-662.
72. Sowers JR, Lester M. Diabetes and cardiovascular disease. Diabetes Care 1999; 22 (Suppl 3): c14-c20.
73. Chandalia M, Garg A, Lutjohann D, Von Bergmann K, Grundy S, Brinkley LJ. Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus. N Engl J Med 2000; 342: 1392-1398.
74. Borghouts LB, Keizer HA. Exercise and insulin sensitivity: a review. Int J Sports Med 2000; 21: 1-12.
75. Goodyear LJ, Kahn BB. Exercise, glucose transport, and insulin sensitivity. A Rev Med 1998; 49: 235-261
76. Axelsson T, Jansson PA, Smith U, Eliasson B. Nicotine infusion acutely impairs insulin sensitivity in type 2 diabetic patients but not in healthy subjects. J Intern Med 2001; 249: 539-544.
77. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350.
78. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
79. Gokcel A, Karakose H, Ertorer EM, Tanaci N, Tutuncu NB, Guvener N. Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care 2001; 24: 1957-1960.
80. Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonesca VA. Nonhypoglycemic effects of thialodinediones. Ann Intern Med 2001; 134: 61-71.
81. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 574-579.
82. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285(19).
83. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survvival Study (4S). Lancet 1994; 344: 1383-1389.
84. Sacks FM, Pheffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-1009.
85. Rader DJ. Pathophysiology and management of high-density lipoprotein cholesterol. Am J Cardiol 1999; 83: 22F-24F.
86. The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: Sixth report. Arch Intern Med 1997; 157: 2413-2446.
87. Heart Outcome Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
88. Hansson L, Zanchetti A, Carruthers SG, et al. for the HOT study group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
89. Kasiske BL, Kalil RS, Ma JZ, et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118: 129-138.
90. EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependant diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787-1792.
91. Ura N, Higashiiura K, Shimamoto. The mechanisms of insulin sensitivity improving effects of angiotensin converting enzyme inhibitor. Immunopharmacology 1999; 44: 153-159.
92. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342: 905-912.
93. Kendall MJ, Lynch KP, Hjalmarson A, Kjekshus J. Beta-blockers and sudden cardiac death. Ann Intern Med 1995; 123: 358-367.
94. Jonas M, Reicher-Reiss H, Boyko V, et al. (Bezafibrate Infarction Prevention [BIP] Study Group). Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Am J Cardiol 1996; 77: 1273-1277.